Bioharvest Sciences Inc. (BHST)
Summary
Fiinu shares jump over 6% as Conister Bank platform enters production
Fiinu (AIM: BANK), the UK fintech group, rose over 6% to 4p on Friday after its Plugin Overdraft platform moved into production ahead of a planned year-end...
BioHarvest Sciences plans Tel Aviv Stock Exchange dual listing
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) plans to pursue a dual listing of its ordinary shares on the Tel Aviv Stock Exchange (TASE), with trading expected to begin on September 8, 2026. The company, which is listed on the Nasdaq Capital Market, expects the TASE listing to provide investors in Israel with access to its shares.
BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript
BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript
Bioharvest Sciences Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 154 | $952.16 | $394.24 | -$557.92 | -58.6% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 2 | $6 | $3.68 | -$2.32 | -38.67% |
 Kevin Bresler TD Waterhouse Canada Inc. | 23,827 | $124,739.39 | $51,466.32 | -$73,273.07 | -58.74% |
 Jeffrey M Bernstein Silverberg Bernstein Capital Management LLC | 57,723 | $202,449.76 | $124,681.68 | -$77,768.08 | -38.41% |
Bioharvest Sciences Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SM Sean McGowan Roth Capital | 27,753.44 | $59,669.89 | $57,449.62 | -$2,220.27 | -3.72% |
Bioharvest Sciences Inc. (BHST) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bioharvest Sciences Inc. ever had a stock split?
Bioharvest Sciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Zaki Rakib CEO | NASDAQ (NMS) Exchange | 09076J207 CUSIP |
| CA Country | 89 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
BioHarvest Sciences Inc. is a trailblazer in the biotechnology industry, focusing on the innovative development of botanical synthesis platform technology. This advanced technology enables the company to cultivate essential ingredients found in various fruits and plants without the necessity of growing the plants themselves. Positioned at the intersection of science and nature, BioHarvest Sciences is committed to bringing forth therapeutic solutions that are both science-based and clinically proven, catering to the nutraceuticals and pharmaceuticals sectors. In addition to its role as a product innovator, the company extends its expertise to serve as a contract development and production organization (CDMO), offering its services to clients in need of diverse molecules. With operations spanning across Israel and the United States, and headquartered in Vancouver, Canada, BioHarvest Sciences Inc. is pioneering a sustainable approach to biotechnology, aimed at enhancing health and wellness through its unique platform.
Products and Services
- VINIA
VINIA is a premier product from BioHarvest Sciences Inc., featuring a red grape cell dietary supplement that is rich in the natural matrix of polyphenols found in red grapes. This innovative product exemplifies the company's capability to harness the power of botanical synthesis technology, delivering the health benefits of red grapes in a concentrated form. VINIA is designed to support cardiovascular health, antioxidant activity, and overall wellness, reflecting BioHarvest Sciences Inc.'s commitment to leveraging natural ingredients for maximum health benefits.
- Contract Development and Production Organization (CDMO) Services
As a CDMO, BioHarvest Sciences Inc. offers a range of specialized services to clients seeking to develop and produce various molecules. This aspect of the company's operations showcases its technical expertise and flexible capability to meet diverse client needs. From initial development stages through to production, BioHarvest Sciences Inc. works closely with its partners to ensure the highest standards of quality and efficiency are met, thereby reinforcing its position as a trusted collaborator in the biotechnology and pharmaceutical industries.
